Protagenic Therapeutics Inc. is facing regulatory challenges after receiving notice from Nasdaq regarding its failure to meet continued listing requirements, specifically the minimum stockholders' equity and timely filing of periodic reports. As a result, the company's securities are set to be delisted from Nasdaq, with trading expected to move to the over-the-counter (OTC) market beginning January 5, 2026. The company is evaluating steps to regain compliance with Nasdaq listing standards and is considering seeking relisting on a national securities exchange. There are currently no mentions of tariffs impacting the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000263), on January 05, 2026, and is solely responsible for the information contained therein.